PAINCAGE

"The NGF system and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain"

Coordinatore	SCUOLA NORMALE SUPERIORE DI PISA    more  Organization address address: Piazza dei Cavalieri 7 city: Pisa postcode: 56126 contact info Titolo: Ms. Nome: Larissa Cognome: Zoni Email: send email Telefono: 39050509376 Fax: 39050509334
Nazionalità Coordinatore	Italy [IT]
Totale costo	7˙878˙342 €
EC contributo	5˙860˙831 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-04-01   -   2017-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	SCUOLA NORMALE SUPERIORE DI PISA  Organization address address: Piazza dei Cavalieri 7 city: Pisa postcode: 56126 contact info Titolo: Ms. Nome: Larissa Cognome: Zoni Email: send email Telefono: 39050509376 Fax: 39050509334	IT (Pisa)	coordinator	1˙159˙329.00
2	EUROPEAN BRAIN RESEARCH INSTITUTE R ITA LEVI-MONTALCINI FONDAZIONE*EBRI  Organization address address: Via del Fosso di Fiorano 64 city: ROMA postcode: 143 contact info Titolo: Dr. Nome: Silvia Cognome: Marinelli Email: send email Telefono: +39 06501703114 Fax: +39 06501703329	IT (ROMA)	participant	837˙898.00
3	AARHUS UNIVERSITET  Organization address address: Nordre Ringgade 1 city: AARHUS C postcode: 8000 contact info Titolo: Mrs. Nome: Lone Cognome: Romar Larsen Email: send email Telefono: +45 5144 7499	DK (AARHUS C)	participant	776˙000.00
4	MEDIZINISCHE UNIVERSITAET WIEN  Organization address address: SPITALGASSE 23 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Jürgen Cognome: Sandkühler Email: send email Telefono: +43140160 34101	AT (WIEN)	participant	710˙215.00
5	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44020 7848 8181	UK (LONDON)	participant	610˙214.00
6	GENOMNIA SRL  Organization address address: CORSO MAGENTA 56 city: MILANO postcode: 20123 contact info Titolo: Dr. Nome: Anna Cognome: Moles Email: send email Telefono: +39 0293305700 Fax: +39 0293305777	IT (MILANO)	participant	505˙143.00
7	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Mr. Nome: Jérémy Cognome: Bonnassies Email: send email Telefono: +33 5 5757 3637 Fax: +33 5 57 57 3655	FR (PARIS)	participant	498˙384.00
8	UNIVERSIDAD DE SALAMANCA  Organization address address: "Patio de Escuelas, 1" city: SALAMANCA postcode: 37008 contact info Titolo: Prof. Nome: María De Los ángeles Cognome: Serrano García Email: send email Telefono: +34 923 294 430 Fax: +34 923 294 502	ES (SALAMANCA)	participant	492˙314.00
9	LEVICEPT LTD  Organization address address: RAMSGATE ROAD DISCOVERY PARK INNOVATION HOUSE city: SANDWICH KENT postcode: CT13 9ND contact info Titolo: Dr. Nome: Simon Cognome: Westbrook Email: send email Telefono: +44 7590815398	UK (SANDWICH KENT)	participant	271˙334.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'So far, there are no effective treatments for neuropathic pain (NP), and current treatments suffer from serious unwanted side effects. The NGF ligand-receptor system has recently emerged as a novel target for NP of great therapeutic potential, a master regulator, controlling both neuropathic and inflammatory components. Besides being a multi-component system, it also modulates the endocannabinoid (EC) signalling. Blocking the NGF signaling system is therefore a rational and thoroughly validated approach to pain therapy. Extensive evidence for potent analgesic efficacy of antiNGF mAbs has been obtained in preclinical models and in clinical trials,showing remarkable analgesic efficacy and creating great expectations for this new class of analgesic compounds.However, potential safety concerns related to off-target side effects have been raised and recently the FDA called for more preclinical research. To fully exploit the huge therapeutic potential of NGF system, we built a consortium of leading researchers in the NGF, EC and pain scientific arena.The innovative proposal will investigate new strategies for the treatment of different NP forms, based on the NGF system and its interplay with EC signalling, focussing at different levels of the pain transmission and perception systems. The project results will provide solid, mechanism-based grounds for the development of already identified second-generation therapeutics, based on the “NGF target” system, as well as for the identification and validation of new druggable targets emerging from the elucidated mechanisms. It will also identify biomarkers for NP, validated in animal models and clinical samples, that could result in future clinical benefits, for the stratification of patients suffering from different neuropathies and their treatment. The project will contribute to the understanding and controlling NP mechanisms, with an interdisciplinary approach, leading to the development of next-generation NGF targeting drugs.'